These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
231 related items for PubMed ID: 11145192
21. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. Schmitt C, Kaeser B, Riek M, Bech N, Kreuzer C. Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013 [Abstract] [Full Text] [Related]
22. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. Liu W, Meng Q, Sun Y, Wang C, Huo X, Liu Z, Sun P, Sun H, Ma X, Liu K. Cell Physiol Biochem; 2018 Mar; 51(4):1616-1631. PubMed ID: 30497065 [Abstract] [Full Text] [Related]
23. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells. Patel J, Hussain A, Pal D, Mitra AK. Am J Ther; 2004 Mar; 11(2):114-23. PubMed ID: 14999363 [Abstract] [Full Text] [Related]
28. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors. Shibata N, Matsumura Y, Okamoto H, Kawaguchi Y, Ohtani A, Yoshikawa Y, Takada K. J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568 [Abstract] [Full Text] [Related]
29. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Ye ZW, Camus S, Augustijns P, Annaert P. Biopharm Drug Dispos; 2010 Mar; 31(2-3):178-88. PubMed ID: 20238377 [Abstract] [Full Text] [Related]
30. New anti-HIV agents and targets. De Clercq E. Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088 [Abstract] [Full Text] [Related]
32. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. Dupuis ML, Flego M, Molinari A, Cianfriglia M. HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546 [Abstract] [Full Text] [Related]
34. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Alsenz J, Steffen H, Alex R. Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072 [Abstract] [Full Text] [Related]
35. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Fukuda Y, Takenaka K, Sparreboom A, Cheepala SB, Wu CP, Ekins S, Ambudkar SV, Schuetz JD. Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562 [Abstract] [Full Text] [Related]
39. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797 [Abstract] [Full Text] [Related]
40. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH. Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]